Nabil Ahmed, M.D., M.Sc.
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
- M.D., Faculty of Medicine, Cairo University, Cairo, Egypt
- Clinical Fellowship, Pediatric Hematology and Oncology, National Cancer Institute, Cairo University, Egypt
- Pediatric Residency, Lincoln Hospital, Weill-Cornell Medical College, New York and Children’s Hospital of New Jersey (CHNJ), Mount Sinai School of Medicine. Newark, NJ
- Fellowship, Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, TX
- American Board of Pediatrics (ABP), Pediatrics
- Egyptian Ministry of Health and Population
- American Board of Pediatrics (ABP), Pediatric Hematology and Oncology
- American Society of Bone Marrow Transplantation (ASBMT)
- American Society of Clinical Oncology (ASCO)
- American Society of Pediatric Hematology and Oncology (ASPHO)
- American Society of Hematology (ASH)
- Egyptian Medical Syndicate.
Clinical Special Interests
- Bone Marrow Transplantation
- Cell and Gene Therapy
Three-hour time lapse of HER2-specific T cells destroying a brain tumor cell
Dr. Nabil Ahmed is interested in the adoptive cellular immunotherapy for solid tumors. He employs genetically engineered T cells that express tumor-specific chimeric antigen receptors (CARs) to target tumor restricted antigens. CARs are artificial molecules that enable the patient's T cells to be activated upon contact with these tumor antigens. This therapeutic approach has the major advantage of offering specific killing of malignant cells that express a tumor-restricted antigen with minimal bystander effects. In a series of preclinical studies, Dr. Ahmed has shown that HER2-specific T cells from healthy donors and brain tumor patients recognize and kill HER2 positive medulloblastoma and glioblastoma multiforme (GBM) cell lines as well as autologous primary tumors. In addition, adoptive transfer of HER2-specific T cells induced regression of established medulloblastomas and GBM in an orthotopic xenograft models. At present, Dr. Ahmed is studying methods to improve the anti-tumor efficacy, growth and survival of genetically modified HER2-specific T cells in the central nervous system and their ability to home to tumor sites to eradicate loco-regionally advanced disease. In his ongoing work, Dr. Ahmed is focusing on the development of an innovative immunotherapy approach for pediatric bone sarcomas and breast cancer.
- Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov;14(11):1298-304.
- Ahmed N, Chizhevsky V. Acute hepatic sequestration associated with pneumococcal infection in a 5-year-old Boy with sickle beta degrees -thalassemia: a case report and review of the literature. J Pediatr Hematol Oncol. 2007 Oct;29(10):720-4.
- Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. Pediatr Blood Cancer. 2007 Nov;49(6):786-92.
- Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15;67(12):5957-64.
- Leen A, Ratnayake M, Foster A, Heym K, Ahmed N, Rooney CM, Gottschalk S. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan;30(1):96-107.
- Ahmed N, Heslop HE. Viral lymphomagenesis. Curr Opin Hematol. 2006 Jul;13(4):254-9.